Metraipolis › archive › dc_a799cc90ae6b

Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety — Europe PMC PMID:41089698

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41089698
DOI
10.3389/fimmu.2025.1664519
License (as archived)
solo-consultazione
Archived
2026-11-09T16:53:57.825Z
SHA-256 of the archived text
acc90ee3a5eef356541410eaadf66761006c8f8126a917b77bbe403d3f9af40c
Stable URL of this page
https://metraipolis.com/documento/dc_a799cc90ae6b

How to cite

Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety — Europe PMC PMID:41089698 — Europe PMC (en), https://europepmc.org/article/MED/41089698 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a799cc90ae6b (Metraipolis archive dc_a799cc90ae6b, sha256 acc90ee3a5eef356541410eaadf66761006c8f8126a917b77bbe403d3f9af40c)
BibTeX
@misc{dca799cc90ae6b,
  title = {Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety — Europe PMC PMID:41089698},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41089698},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a799cc90ae6b; sha256 acc90ee3a5eef356541410eaadf66761006c8f8126a917b77bbe403d3f9af40c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41089698. Agents can read the archived copy with the MCP tool read_document.